Latest News
Decoy Therapeutics expands antiviral platform into Ebola and filovirus research
27 July 2026 - Biotechnology company Decoy Therapeutics Inc (Nasdaq: DCOY) reported on Monday that a D-MAV antiviral candidate demonstrated in vitro activity against wild-type Ebola Zaire virus, expanding the company's Designable Multi-Antiviral...
AcuCort secures renewed FDA fee waiver ahead of planned NDA submission
27 July 2026 - Swedish pharmaceutical company AcuCort AB (Spotlight Stock Market: ACUC), developer of the rapidly dissolving dexamethasone oral film Zeqmelit, said on Monday it has received a renewed Small Business Waiver from the US Food and Drug Ad...
Yarrow Bioscience completes VYNE merger and begins Phase 2 trial of YB-101
27 July 2026 - Clinical-stage biotechnology company Yarrow Bioscience Inc (Nasdaq:YARW) announced on Monday that it has completed its merger with VYNE Therapeutics Inc and closed previously announced private financings totalling approximately USD200m...
Harbour BioMed and Sinopharm establish innovation R&D consortium
27 July 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) declared on Monday that it has entered into a strategic collaboration with China National Pharmaceutical Group Co Ltd (Sinopharm) to establish the Sinopharm - Harbour BioMed Innova...
argenx agrees to acquire Forte Biosciences for USD2.2bn to add anti-CD122 antibody FB102
27 July 2026 - Immunology innovation company argenx (Euronext & Nasdaq: ARGX) disclosed on Monday that it has entered into a definitive agreement to acquire biopharmaceutical company Forte Biosciences Inc (Nasdaq: FBRX) for USD77 per share in cas...